161 related articles for article (PubMed ID: 28800175)
1. Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia.
Wang W; Bochtler T; Wuchter P; Manta L; He H; Eckstein V; Ho AD; Lutz C
Eur J Haematol; 2017 Nov; 99(5):392-398. PubMed ID: 28800175
[TBL] [Abstract][Full Text] [Related]
2. The molecular signature of AML mesenchymal stromal cells reveals candidate genes related to the leukemogenic process.
Binato R; de Almeida Oliveira NC; Du Rocher B; Abdelhay E
Cancer Lett; 2015 Dec; 369(1):134-43. PubMed ID: 26279521
[TBL] [Abstract][Full Text] [Related]
3. Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implications.
Won EJ; Kim HR; Park RY; Choi SY; Shin JH; Suh SP; Ryang DW; Szardenings M; Shin MG
BMC Cancer; 2015 Apr; 15():217. PubMed ID: 25881148
[TBL] [Abstract][Full Text] [Related]
4. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
[TBL] [Abstract][Full Text] [Related]
6. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
7. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells.
Tian C; Zheng G; Zhuang H; Li X; Hu D; Zhu L; Wang T; You MJ; Zhang Y
J Cell Physiol; 2017 Jun; 232(6):1387-1395. PubMed ID: 27696394
[TBL] [Abstract][Full Text] [Related]
9. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
[TBL] [Abstract][Full Text] [Related]
10. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ
Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865
[TBL] [Abstract][Full Text] [Related]
11. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
12. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
13. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
15. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
16. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
[TBL] [Abstract][Full Text] [Related]
17. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.
Houshmand M; Soleimani M; Atashi A; Saglio G; Abdollahi M; Nikougoftar Zarif M
Tissue Eng Part C Methods; 2017 Feb; 23(2):72-85. PubMed ID: 28007011
[TBL] [Abstract][Full Text] [Related]
18. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
19. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
20. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]